Hemoglobin Nanocrystals for Drugs Free, Synergistic Theranostics of Colon Tumor.
Renbin ZhouHao XuJunle QuTymish Y OhulchanskyyPublished in: Small (Weinheim an der Bergstrasse, Germany) (2022)
The conventional approach in cancer nanomedicine involves advanced drug nanocarriers delivering preloaded therapeutics to targeted tumor sites to maximize drug efficiency. However, both cancer drugs and nanocarriers inevitably produce side effects and systemic toxicity. Herein, hemoglobin nanocrystals (HbC) as drug-free theranostic nanoformulations with the tumor microenvironment (TME) activated diagnostic and therapeutic abilities towards colon tumors are introduced. HbC can release Fe 2+ oxidized to Fe 3+ in the Fenton reaction with tumor endogenous H 2 O 2 , concurrently with the generation of cytotoxic hydroxyl radicals (•OH) that allow for chemodynamic therapy (CDT). Furthermore, in situ-produced Fe 3+ reacts with colon tumor-abundant H 2 S, resulting in the production of Fe 1- x S, which provides magnetic resonance imaging (MRI) contrast and allows for NIR light-inducible photothermal therapy (PTT). In vitro and in vivo studies revealed that HbC produced CDT towards 4T1 tumors, and MRI-guided, synergistically enhanced combination of CDT and PTT against H 2 S abundant colon tumors (CT26), with negligible toxicity towards normal tissues, enlightening HbC as highly efficient and biocompatible TME activated theranostic nanoplatform specific against colon cancer without any traditional drugs and drug carriers.
Keyphrases
- magnetic resonance imaging
- cancer therapy
- contrast enhanced
- highly efficient
- photodynamic therapy
- drug release
- drug delivery
- drug induced
- papillary thyroid
- computed tomography
- oxidative stress
- magnetic resonance
- adverse drug
- emergency department
- squamous cell
- diffusion weighted imaging
- squamous cell carcinoma
- small molecule
- metal organic framework
- stem cells
- single cell
- aqueous solution
- electronic health record
- energy transfer